The plexiform neurofibroma microenvironment
- PMID: 22821631
- PMCID: PMC3460056
- DOI: 10.1007/s12307-012-0115-x
The plexiform neurofibroma microenvironment
Abstract
Dynamic interactions between tumorigenic cells and surrounding cells, including immunomodulatory hematopoietic cells, can dictate tumor initiation, progression, and transformation. Hematopoietic-stromal interactions underpin the plexiform neurofibroma, a debilitating tumor arising in individuals afflicted with Neurofibromatosis type 1 (NF1), a common genetic disorder resulting from mutations in the NF1 tumor suppressor gene. At the tissue level, plexiform neurofibromas demonstrate a complex microenvironment composed of Schwann cells, fibroblasts, perineural cells, mast cells, secreted collagen, and blood vessels. At the cellular level, specific interactions between these cells engender tumor initiation and progression. In this microenvironment hypothesis, tumorigenic Schwann cells secrete pathological concentrations of stem cell factor, which recruit c-kit expressing mast cells. In turn, activated mast cells release inflammatory effectors stimulating the tumorigenic Schwann cells and their supporting fibroblasts and blood vessels, thus promoting tumor expansion in a feed-forward loop. Bone marrow transplantation experiments in plexiform neurofibroma mouse models have shown that tumorigenesis requires Nf1 haploinsufficiency in the hematopoietic compartment, suggesting that tumor microenvironments can depend on intricate interactions at both cellular and genetic levels. Overall, our continued understanding of critical tumor-stromal interactions will illuminate novel therapeutic targets, as shown by the first-ever successful medical treatment of a plexiform neurofibroma by targeted inhibition of the stem cell factor/c-kit axis.
Similar articles
-
Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells.Curr Opin Hematol. 2010 Jul;17(4):287-93. doi: 10.1097/MOH.0b013e328339511b. Curr Opin Hematol. 2010. PMID: 20571392 Free PMC article. Review.
-
Mast cells and the neurofibroma microenvironment.Blood. 2010 Jul 15;116(2):157-64. doi: 10.1182/blood-2009-09-242875. Epub 2010 Mar 16. Blood. 2010. PMID: 20233971 Free PMC article. Review.
-
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.Cell. 2008 Oct 31;135(3):437-48. doi: 10.1016/j.cell.2008.08.041. Cell. 2008. PMID: 18984156 Free PMC article.
-
Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.Annu Rev Pathol. 2012;7:469-95. doi: 10.1146/annurev-pathol-011811-132441. Epub 2011 Nov 7. Annu Rev Pathol. 2012. PMID: 22077553 Free PMC article. Review.
-
The NF1+/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation.Cancers (Basel). 2024 Feb 29;16(5):994. doi: 10.3390/cancers16050994. Cancers (Basel). 2024. PMID: 38473354 Free PMC article. Review.
Cited by
-
Intercostal aneurysm causing spinal cord compression in an NF1 patient.Eur Spine J. 2015 May;24(5):940-4. doi: 10.1007/s00586-013-2778-5. Epub 2013 Apr 19. Eur Spine J. 2015. PMID: 23604938
-
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.Oncotarget. 2017 May 30;8(47):82037-82048. doi: 10.18632/oncotarget.18301. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137242 Free PMC article.
-
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Pediatr Blood Cancer. 2014 Sep;61(9):1598-602. doi: 10.1002/pbc.25041. Epub 2014 Apr 22. Pediatr Blood Cancer. 2014. PMID: 24753394 Free PMC article. Clinical Trial.
-
Vascular anomaly in the levator aponeurosis of neurofibromatosis type 1.Int J Ophthalmol. 2017 Apr 18;10(4):656-657. doi: 10.18240/ijo.2017.04.25. eCollection 2017. Int J Ophthalmol. 2017. PMID: 28503443 Free PMC article. No abstract available.
-
Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening.Exp Neurol. 2018 Jan;299(Pt B):289-298. doi: 10.1016/j.expneurol.2017.10.012. Epub 2017 Oct 19. Exp Neurol. 2018. PMID: 29055717 Free PMC article.
References
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous